VIPROSTOL

Details

Stereochemistry	MIXED
Molecular Formula	C23H36O5
Molecular Weight	392.5289
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 4
E/Z Centers	2
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCC(O)(C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(=O)OC)C=C

InChI

InChIKey=TWCQWABAGCMHLL-ROVQGQOSSA-N

InChI=1S/C23H36O5/c1-4-6-15-23(27,5-2)16-11-13-19-18(20(24)17-21(19)25)12-9-7-8-10-14-22(26)28-3/h5,7,9,11,13,18-19,21,25,27H,2,4,6,8,10,12,14-17H2,1,3H3/b9-7-,13-11+/t18-,19-,21-,23?/m1/s1

HIDE SMILES / InChI

Molecular Formula	C23H36O5
Molecular Weight	392.5289
Charge	0
Count

Stereochemistry	EPIMERIC
Additional Stereochemistry	No
Defined Stereocenters	3 / 4
E/Z Centers	2
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2212146 | https://www.ncbi.nlm.nih.gov/pubmed/4083568

Viprostol (also known as CL115,347), a prostaglandin E2 congener that was studied as an antihypertensive agent. Viprostol has a potent and prolonged blood pressure lowering effect in many models of hypertension. In clinical studies, viprostol has been demonstrated to lower arterial blood pressure significantly in man following transdermal and/or intravenous administration. The antihypertensive action of viprostol has been suggested to be the result of peripheral vasodilatation. In addition, the drug participated in a clinical trial in normal subjects and in patients with Raynaud's phenomenon. It was found the optimal dosage was 1000 ug; the effect could last for 84 hours; higher dosage may be associated with a "steal" phenomenon.

Approval Year

PubMed

Title	Date	PubMed
CL 115,347 (DHV-PGE2 ME): a new orally and topically active prostaglandin antihypertensive agent.	1983 Feb	6571821
Antilipolytic activity of viprostol, a transdermally active antihypertensive PGE2 analog.	1987 May	2438724
Deposition of viprostol (a synthetic PGE2 vasodilator) in the skin following topical administration to laboratory animals.	1987 Sep	3120427
Pre-systemic metabolism of viprostol in the monkey following oral and topical administration.	1988 Jul	3176518
Transdermal absorption and skin metabolism of viprostol, a synthetic prostaglandin E2 analogue.	1989-1990	2701170
Transdermal viprostol in the treatment of male pattern baldness.	1990 Sep	2212146

Sample Use Guides

In Vivo Use Guide

substance is absorbed transdermally from a patch placed on the skin. In a placebo-controlled trial the vasodilatory effect of single incremental dosage, 500 mcg, 1000 mcg and 1500 mcg

Route of Administration: Transdermal

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:16:20 GMT 2023` Edited by `admin` on `Fri Dec 15 16:16:20 GMT 2023`
Record UNII	O2Y6I4Y8TF
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

VIPROSTOL

Official Name

English

VIPROSTOL [MART.]

Common Name

English

VIPROSTOL [USAN]

Common Name

English

PROSTA-5,13-DIEN-1-OIC ACID, 16-ETHENYL-11,16-DIHYDROXY-9-OXO-, METHYL ESTER, (5Z,11A,13E)-(±)-

Common Name

English

viprostol [INN]

Common Name

English

CL 115,347

Code

English

CL-115347

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C78568